This trial is for adults with advanced cancer who have no other treatment options. The purpose is to find the highest dose of BI 770371 that people can tolerate when taken alone or with ezabenlimab.
2 Primary · 4 Secondary · Reporting Duration: up to 2 years
Experimental Treatment
42 Total Participants · 2 Treatment Groups
Primary Treatment: BI 770371 · No Placebo Group · Phase 1
Age 18+ · All Participants · 8 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: